The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter phase II randomized study of customized neoadjuvant therapy versus standard chemotherapy (CT) in non-small cell lung cancer (NSCLC) patients with resectable stage IIIA(N2) disease (CONTEST trial).
Francesco Grossi
No relevant relationships to disclose
Erika Rijavec
No relevant relationships to disclose
Giulia Barletta
No relevant relationships to disclose
Claudio Sini
No relevant relationships to disclose
Carlo Genova
No relevant relationships to disclose
Maria Giovanna Dal Bello
No relevant relationships to disclose
Giovanni Battista Ratto
No relevant relationships to disclose
Mauro Truini
No relevant relationships to disclose
Domenico Franco Merlo
No relevant relationships to disclose